Legal Guide
Registration is a dossier discipline: form, quality, proof, and a named responsible person.
Quick answer: Drug Regulation Authority of Pakistan (DRAP) registers pharmaceutical and biological products, licenses premises, oversees imports through NOCs and import registrations, and enforces quality through GMP inspection and pharmacovigilance reporting. Both consolidated facilities and importers are operators – not paperwork filers – with statutory duties that survive registration. Failure modes are concentrated in dossiers (expired stability data, missing reference standards), quality systems, and price-file mismatches.
Registration scope
- Drug products: approval requires product data per formulation and strength, including stability, manufacturing site, and packaging
- Reference products: bio-equivalence anchors and standards; licensing of manufacturing units with premises inspections
- Contained import channels: NOC plus import licence for unregistered products in defined pathways (hospitals, clinical needs)
- Biologicals and vaccines: distinct evaluation tracks for clinical and stability expectations
- Medical devices: a developing regime: verify current status before designing an import or localisation program
Pricing and supply
Pricing remains a regulator-supervised area with notified ceiling prices and hardship categories, subject to policy shifts; marketing authorisation alone does not settle price. Registries and distributor models should be built on a confirmed price file – not a memorandum of understanding with a distributor – because real-world disputes are pricing-led. Distribution contracts should carry registrations as conditions precedent, and material-change clauses so that either side can respond when DRAP updates formulation or site data.
Market-entry and structuring wholesalers require more than registration: the corporate form (SECP), tax registration, and contracting stack are handled jointly by our company registration and foreign investment teams, as with other sectors – see the pharmaceuticals industry practice.
Quality, pharmacovigilance, and compliance supervision
Post-registration life is where enforcement bites: GMP inspections, batch-related quality complaints, recalls and I砍 pharmacy incidents, pharmacovigilance expectations (adverse-event reporting, PSURs), and label/leaflet accuracy are maintained year to year. Registration holders should assign a responsible person, run a complaints-to-action register, and keep the marketing/distribution chain under audit – because enforcement enquiries trace products backwards through the chain.
When adjudication or enforcement is already in play
DRAP takes action through show-cause, suspensions, and criminal referrals; the response record should be built with legal input from the first letter. The appellate procedure for registration and licensing decisions is sector-specific. Engage counsel before answering the first show-cause letter – not after a decision issues; assessments of what registration data exists and how it supports the defence are faster at intake. Contact Axiom Chambers via the consultation page.